Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Clinical trials sponsored by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical company focused on biochemical drugs, including heparin products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new biosimilar match Neulasta's power to rebuild white blood cells? Results expected Nov 2026 (estimated)